- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03956823
Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension
A Cohort Study of Telmisartan on Metabolic Components and Left Ventricular Remodeling in Obese Patients With Hypertension
Study Overview
Detailed Description
At present, there are no guidelines for the treatment of obese patients with hypertension. Blood pressure control and effective control of obesity are important therapeutic targets for obesity-associated hypertension. Whether telmisartan can be used as PPAR-γ agonist, unlike other AT-1 receptor antagonists and calcium channel blockers amlodipine, can improve the visceral adipose tissue function and cardiac remodeling in obese patients with hypertension by altering their metabolic components and insulin sensitivity while controlling blood pressure. There is no evidence that telmisartan can reduce cardiac remodeling in obese patients with hypertension.
1.Research contents:
- To evaluate the clinical efficacy of telmisartan or amlodipine in controlling blood pressure, reducing fat accumulation, improving glycolipid metabolism and insulin sensitivity, and reducing cardiac remodeling in obese patients with hypertension;
- To evaluate whether telmisartan can alter metabolic components and insulin sensitivity, improve visceral adipose tissue function and reduce cardiac remodeling in obese patients with hypertension by blocking AT-1 receptor and partially activating PPAR-gamma, which is different from other AT-1 receptor antagonists and calcium channel blockers amlodipine.
2.Research population 2.1 Entry criteria
Only those who possess the following four conditions can enter the study:
- Essential hypertension patients (including confirmed hypertension without regular treatment, average blood pressure (≥160 or/and 100 mmHg) in two follow-up visits; or hypertension under combined antihypertensive treatment; or unsatisfactory blood pressure control with single drug treatment, blood pressure above 140 or/and 90 mmHg);
- Age ranges from 18 to 79;
- Body mass index, BMI (≥30 kg/m2), or waist circumference, male (≥102 cm), female (≥ 88 cm);
- Ability to provide informed consent。
2.2 exclusion criteria
One of the following is not included:
(1) secondary hypertension; (2) acute cardiovascular and cerebrovascular events within 3 months; (3) severe cardiomyopathy, rheumatic heart disease, congenital heart disease;(4) unstable angina pectoris; (5) severe liver or kidney disease (ALT increased by 2 times; Creatinine > 2. 5 mg/dL); (6) malignant tumors; (7) gout; (8) women who are taking birth control pills or are at risk of pregnancy; (9) have a history of allergy to research drugs; (10) patients with specific contraindications to the study drugs; (11) participants in other clinical trials; (12) patients with difficulty in long-term follow-up or poor compliance; (13) the competent doctor considers it inappropriate to participate in clinical research.
3.The input information of the subjects
- Sample source: Since December 2018, patients with essential hypertension were diagnosed in the First Affiliated Hospital of Xi'an Jiaotong University and treated with telmisartan or amlodipine alone under the guidance of doctors;
- Recruitment procedures: selecting the subjects according to inclusion and exclusion criteria, and signing informed consent.
4.Criteria for termination or withdrawal of research subjects
- Those who need revascularization because of myocardial infarction and unstable angina pectoris;
- Heart failure;
- Stroke.
5. Study Groups
- Telmisartan group: Telmisartan 80 mg once a day
- amlodipine group: amlodipine 5 mg once a day
6.Research evaluation index
- Baseline indicators: age, sex, occupation, height, weight, BMI, waist-hip circumference, systolic blood pressure, diastolic blood pressure, heart rate;
- Metabolic indicators: blood lipid, liver function, kidney function, oral glucose tolerance test, simultaneous insulin release test, plasma Glucagon, plasma aldosterone, plasma angiotensin II, abdominal fat distribution
- Fat function: serum leptin, serum adiponectin, serum TNFalpha, serum IL-6, serum hs-CRP, serum PPAR-γ;
- Cardiac remodeling: echocardiographic parameters .
7.Research steps
- Clinical trials are ethically reviewed by ethics committees, and clinical trials are registered;
- Collect cases according to inclusion and exclusion criteria, collect medical history data of subjects, and complete follow-up. At the same time, clinical and biochemical experiments were carried out;
- Comprehensive analysis of experimental data, repetition and supplementation of necessary molecular biological experiments, comprehensive summary of the results, writing and publishing SCI papers and Chinese core journal papers.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gang Tian, doctor
- Phone Number: 0086-18991232420
- Email: tiangang@xjtu.edu.cn
Study Contact Backup
- Name: Lifei Cao, master
- Phone Number: 0086-15829315817
- Email: caolifei1187@stu.xjtu.edu.cn
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China, 710061
- Recruiting
- First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Gang Tian, doctor
- Phone Number: 0086-18991232420
- Email: tiangang@xjtu.edu.cn
-
Contact:
- Lifei Cao, master
- Phone Number: 0086-15829315817
- Email: caolifei1187@stu.xjtu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Essential hypertension patients (including those with unconventional diagnosed hypertension, whose average blood pressure was more than 160 or/and 100 mmHg in two outpatient follow-up visits; or those who were undergoing combined antihypertensive therapy; or those whose blood pressure control was unsatisfactory and whose blood pressure was more than 140 or/and 90 mmHg in single drug treatment);
- The age ranged from 18 to 79 years;
- Body mass index, BMI (≥ 30 kg/m2), or waist circumference, male (≥102 cm), female (≥88 cm);
- Ability to provide informed consent.
Exclusion Criteria:
- Secondary hypertension;
- Acute cardiovascular and cerebrovascular events occurred within 3 months;
- Complicated with severe cardiomyopathy, rheumatic heart disease, congenital heart disease;
- unstable angina pectoris;
- Severe liver or kidney diseases (ALT increased twice; creatinine > 2.5 mg/d1);
- Tumor;
- Gout;
- Women who are taking contraceptives or are at risk of pregnancy; -Has a history of allergy to research drugs;
- Those who have clear contraindications to the research drugs;
- Those who are participating in other clinical trials;
- Those who are not easy to follow up for a long time or have poor compliance;
- Doctors in charge do not consider it advisable to participate in clinical research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telmisartan
generic name:telmisartan;dosage form:80 mg;dosage:80 mg;frequency:once a day;duration:June , 2019-June , 2021
|
Telmisartan group: telmisartan 80 mg once a day
|
Active Comparator: Amlodipine
generic name: amlodipine;dosage form:5mg;dosage:5mg;frequency:once a day;duration:June , 2019-June , 2021
|
amlodipine group: amlodipine 5 mg once a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Revascularization for myocardial infarction and unstable angina pectoris
Time Frame: From date of randomization until the date of first documented progression,assessed up to 24 months
|
Revascularization for myocardial infarction and unstable angina pectoris
|
From date of randomization until the date of first documented progression,assessed up to 24 months
|
Heart failure
Time Frame: From date of randomization until the date of first documented progression,assessed up to 24 months
|
Heart failure
|
From date of randomization until the date of first documented progression,assessed up to 24 months
|
stroke
Time Frame: From date of randomization until the date of first documented progression,assessed up to 24 months
|
stroke
|
From date of randomization until the date of first documented progression,assessed up to 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gang Tian, doctor, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Telmisartan
Other Study ID Numbers
- XJTU1AF-CRF-2018-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on telmisartan
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetic NephropathiesJapan
-
Boehringer IngelheimCompleted
-
Laboratorio Elea Phoenix S.A.Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBACompleted